Codexis, Inc. (CDXS)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.46+2.82%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CDXS
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | 77.7 | 70.4 | 59.3 | 70.1 | 138.6 | 104.8 | 69.1 | 68.5 | 60.6 | 50.0 | 48.8 | 41.8 | 35.3 | 31.9 | 88.3 | 123.9 |
| Total Revenues | — | — | — | — | 138.6 | 104.8 | 69.1 | 68.5 | 60.6 | 50.0 | 48.8 | 41.8 | 35.3 | 31.9 | 88.3 | 123.9 |
| Cost of Revenues | 10.1 | 9.3 | 16.3 | 12.8 | 38.0 | 22.2 | 13.7 | 15.6 | 12.6 | — | — | — | — | — | — | — |
| Operating Expenses & Income | ||||||||||||||||
| Selling, General & Admin | 43.1 | 47.1 | 55.1 | 53.3 | 52.2 | 49.3 | 35.0 | 31.5 | 29.3 | 29.0 | 25.4 | 22.3 | 21.9 | 26.9 | 31.4 | 36.9 |
| R&D Expenses | 48.7 | 52.3 | 46.3 | 58.9 | 80.1 | 55.9 | 44.2 | 33.9 | 30.0 | 29.7 | 22.2 | 20.7 | 22.8 | 31.6 | 56.8 | 61.0 |
| Operating Income | (27.7) | (41.7) | (58.5) | (68.1) | (34.9) | (22.7) | (23.9) | (12.5) | (11.3) | (23.0) | (8.6) | (7.8) | (19.1) | (41.1) | (30.5) | (15.9) |
| Earnings from Continuing Operations | ||||||||||||||||
| Interest Expense | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.0 | 0.0 | — |
| Interest & Investment Income | 2.5 | 2.6 | 3.7 | 4.2 | 1.4 | 0.5 | 0.4 | 1.3 | 0.7 | 0.1 | 0.1 | 0.0 | 0.0 | 0.1 | 0.3 | 0.3 |
| Net Interest Expenses | — | — | — | — | — | — | — | — | — | — | — | — | — | (0.0) | (0.3) | — |
| Asset Writedown | — | — | 0.2 | 10.0 | 0.0 | — | — | — | — | — | — | — | 1.6 | 1.6 | — | — |
| EBT, Incl. Unusual Items | (30.7) | (43.9) | (65.2) | (76.2) | (33.3) | (21.1) | (23.7) | (11.9) | (10.9) | (22.9) | (8.6) | (7.9) | (19.3) | (41.4) | (30.6) | (16.3) |
| Income Tax Expense | 0.1 | 0.0 | 0.0 | 0.1 | 0.3 | 0.2 | 0.3 | 0.0 | (0.0) | 0.1 | (0.0) | (0.3) | (0.3) | (0.1) | 0.3 | 0.2 |
| Net Income | ||||||||||||||||
| Net Income | (30.7) | (44.0) | (65.3) | (76.2) | (33.6) | (21.3) | (24.0) | (11.9) | (10.9) | (23.0) | (8.6) | (7.6) | (19.1) | (41.3) | (30.9) | (16.6) |
| Per Share | ||||||||||||||||
| Basic EPS | (0.34) | (0.50) | (0.89) | (1.12) | (0.51) | (0.33) | (0.40) | — | — | — | — | — | — | — | — | — |
| Diluted EPS | (0.34) | (0.50) | (0.89) | (1.12) | (0.51) | (0.33) | (0.40) | — | — | — | — | — | — | — | — | — |
| Revenue per Share | 0.85 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 91.1 | 87.1 | 73.4 | 68.1 | 65.3 | 64.6 | 59.4 | — | — | — | — | — | — | 38.2 | 36.8 | — |
| Diluted Weighted Avg Shares | 91.1 | 87.1 | 73.4 | 68.1 | 65.3 | 64.6 | 59.4 | — | — | — | — | — | — | 38.2 | 36.8 | — |
| Supplemental | ||||||||||||||||
| EBITDA | — | (36.5) | (53.6) | (62.6) | (29.5) | — | — | — | — | — | — | — | — | — | — | — |
| EBIT | (27.7) | (41.7) | (58.5) | (68.1) | (34.9) | (22.7) | (23.9) | (12.5) | (11.3) | (23.0) | (8.6) | (7.8) | (19.1) | (41.1) | (30.5) | (15.9) |
| Effective Tax Rate | -0.2% | — | — | -0.1% | -0.8% | -0.9% | -1.4% | -0.1% | 0.3% | -0.4% | 0.5% | 4.3% | 1.3% | 0.2% | -0.9% | -1.5% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.